drugset / Trial / NCT00621647

Seroquel- Agitation Associated With Dementia

NCT00621647

Phase 3 Completed 333 enrolled AstraZeneca
RandomizedFactorialTriple-blindTreatment

Summary

The purpose of this study is to determine how safe and effective Seroquel (quetiapine fumarate) is compared to placebo (a non-drug tablet) for a period of up to 10 weeks in the treatment of agitation symptoms in nursing home or assisted care residents. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2002-09
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule